Jump to content
RemedySpot.com

New Category of Oral Agents for the Potential Treatment of RA and Other Inflammatory Diseases

Rate this topic


Recommended Posts

Posted

Synta and Roche Form Discovery, Development, and Commercialization Alliance

in Inflammation

www.therapeuticsdaily.com/news/article.cfm?contentvalue=596077 & contenttype=newsa\

rchive & channelID=29

From the PharmaLive.com News Archive - Jan. 07, 2009

New Category of Oral Agents for the Potential Treatment of Rheumatoid

Arthritis and Other Inflammatory Diseases

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan 7, 2009 - Synta Pharmaceuticals Corp.

and Roche announced today the formation of a strategic alliance to discover,

develop, and commercialize small-molecule drugs targeting a novel family of

ion channels that are critical to immune cell function, known as calcium

release-activated calcium modulator (CRACM) channels. In preclinical models,

the CRACM inhibitors discovered by Synta potently and selectively inhibit

the secretion of pro-inflammatory factors such as TNF-alpha and IL-2, with

minimal effects on other cells or signaling pathways. This program

represents a new category of oral, targeted, disease-modifying agents for

treating rheumatoid arthritis and a broad range of other inflammatory

diseases.

Under the terms of the agreement, Roche will fund research to be conducted

by Synta during an initial two-year research period. Roche will receive

worldwide rights to develop and commercialize certain products identified

prior to the end of this research period. Synta retains certain

co-development and co-promotion rights. All preclinical, clinical, and

commercial costs will be paid by Roche.

Synta will receive $25 million in upfront cash license fees and committed

research support, of which $9 million will be provided in the form of

research support over the initial research period. Synta will also be

eligible to receive additional payments, for each of three licensed

products, should specified development and commercialization milestones be

successfully achieved. Development milestones across multiple indications of

up to $245 million could be earned for the first product, and up to half of

this amount could be earned for each of the second and third products.

Commercialization milestones of up to $170 million could be earned for each

of three products. Synta will receive tiered royalties on sales of all

approved, marketed products.

" This agreement underscores both the potential of our novel ion channel

inhibitors and the ability of the Synta drug discovery platform to generate

high-quality, first-in-class drug candidates, " said Safi Bahcall, Ph.D.,

President and Chief Executive Officer, Synta. " We believe that combining our

leadership in the CRACM inhibitor field with Roche's expertise in

inflammatory diseases will enable us to accelerate the development of an

exciting new therapeutic category for patients. "

" Synta has the most advanced programme in the field, with its lead candidate

and other promising drug candidates soon progressing into the clinic, " said

Satwant Narula, Roche's Head of Discovery for Inflammation. " The CRACM

channel inhibitor approach has tremendous potential to treat rheumatoid

arthritis and a wide range of other inflammatory diseases that have a high

unmet need for oral, targeted, disease-modifying agents. Roche and Synta

will work closely together to bring these potential therapies to patients. "

" The Synta CRACM inhibitor program generated substantial interest among many

leading global pharmaceutical companies. We believe this interest reflects

the growing scientific excitement around the CRACM target; the size of the

opportunity presented by a new category of disease-modifying agents for

inflammation; and the strength of the Synta intellectual property portfolio

and drug discovery capabilities, " added Albert Hsia, Ph.D., Senior Director,

Business Development, Synta. " We are enthusiastic about working with Roche

in an alliance that combines the strengths of our two companies within a

collaborative framework for rapid development of these promising CRACM

inhibitor compounds. "

About Ion Channel Therapeutics

Ion channels, the gateways in cell membranes that regulate the flow of ions

into and out of cells, play important roles in cell signaling. Certain ion

channels allow electrically excitable cells, such as neurons or muscle

cells, to discharge. Drugs that modulate these ion channels have proven to

be a successful therapeutic category, with dozens of such drugs on the

market and commonly prescribed for the treatment of various neurological and

cardiovascular disorders.

The Synta research program targets an ion channel known as the CRACM

channel, which is believed to play a key role specifically in immune cells

rather than in neurons or muscle cells. CRACM channels regulate the calcium

signaling pathway driving immune cell activation and secretion of TNF-alpha,

IL-2, and other inflammatory factors. The therapeutic importance of

inhibiting this calcium signaling pathway has been demonstrated through

clinical experience with calcineurin inhibitors, such as cyclosporine, which

are potent immunomodulators but have significant toxicities due to the broad

role calcineurin plays in non-immune cells. In contrast to calcineurin,

CRACM channels are believed to be critical exclusively to immune cell

function.

CRACM inhibitors therefore have the potential to achieve potent

anti-inflammatory activity with an improved safety profile, creating a new

category of disease-modifying agents comparable to biologic agents, such as

TNF-alpha inhibitors, but orally available.

The Synta CRACM channel inhibitors have shown strong anti-inflammatory

activity in preclinical studies both in vitro and in vivo, inhibiting T cell

and mast cell activity, including cytokine release, degranulation, and

immune cell proliferation. Potential applications include a wide range of

inflammatory diseases and disorders for which modulating T cell and mast

cell function has been shown to be critical, including rheumatoid arthritis,

asthma, chronic obstructive pulmonary disease (COPD), allergy, transplant

rejection, and other autoimmune diseases and inflammatory conditions.

CRACM Channel References

Vig, M., and Kinet, J.P. Calcium signaling in immune cells. Nat. Immunol.

10, 21-7 (2009).

Feske, S., Prakriya, M., Rao, A., and , R.S. A severe defect in CRAC

Ca2+ channel activation and altered K+ channel gating in T cells from

immunodeficient patients. J. Exp. Med. 202, 651-62 (2005).

, R.S. Calcium signaling mechanisms in T lymphocytes. Annu. Rev.

Immunol. 19, 497-521 (2001).

Cahalan, M.D., and Chandy, K.G. Ion channels in the immune system as targets

for immunosuppression. Curr. Opin. Biotechnol. 8, 749-56 (1997).

Hoth, M., and Penner, R. Depletion of intracellular calcium stores activates

a calcium current in mast cells. Nature. 355, 353-6 (1992).

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on

discovering, developing, and commercializing small-molecule drugs to extend

and enhance the lives of patients with severe medical conditions, including

cancer and chronic inflammatory diseases. Synta has a unique chemical

compound library, an integrated discovery engine, and a diverse pipeline of

clinical- and preclinical-stage drug candidates with distinct mechanisms of

action and novel chemical structures. All Synta drug candidates were

invented by Synta scientists using our compound library and discovery

capabilities. For more information, please visit www.syntapharma.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading

research-focused healthcare groups in the fields of pharmaceuticals and

diagnostics. As the world's biggest biotech company and an innovator of

products and services for the early detection, prevention, diagnosis and

treatment of diseases, the Group contributes on a broad range of fronts to

improving people's health and quality of life. Roche is the world leader in

in-vitro diagnostics and drugs for cancer and transplantation, and is a

market leader in virology. It is also active in other major therapeutic

areas such as autoimmune diseases, inflammatory and metabolic disorders and

diseases of the central nervous system. In 2007 sales by the Pharmaceuticals

Division totaled 36.8 billion Swiss francs, and the Diagnostics Division

posted sales of 9.3 billion francs. Roche has R & D agreements and strategic

alliances with numerous partners, including majority ownership interests in

Genentech and Chugai, and invested over 8 billion Swiss francs in R & D in

2007. Worldwide, the Group employs about 80,000 people. Additional

information is available on the Internet at www.roche.com.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...